艾迪注射液联合替吉奥及奥沙利铂化疗治疗晚期食管癌的效果和安全性

Efficacy and safety of addie injection combined with tegio and oxaliplatin in the treatment of advanced esophageal cancer

目的分析艾迪注射液联合替吉奥、奥沙利铂(SOX)化疗对晚期食管癌患者的效果和安全性。方法抽取2019年7月至2021年7月安阳市第六人民医院收治的晚期食管癌患者80例,按照随机数字表法分为对照组和研究组,每组40例。对照组予以SOX化疗,研究组在对照组治疗基础上加用艾迪注射液。比较两组疾病控制率、不良反应;比较两组治疗前后血管内皮生长因子(VEGF)、T淋巴细胞亚群(CD4^(+)、CD8^(+))、肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)]水平。结果研究组疾病控制率(77.50%,31/40)高于对照组(50.00%,20/40),P<0.05。治疗后,研究组CD4^(+)高于对照组,CD8^(+)低于对照组(P<0.05)。治疗后,研究组VEGF、CEA、CA125水平均低于对照组(P均<0.05)。研究组不良反应发生率(10.00%,4/40)与对照组(25.00%,10/40)比较差异未见统计学意义(P>0.05)。结论艾迪注射液联合SOX化疗治疗晚期食管癌患者,可改善免疫功能,调节肿瘤标志物和VEGF表达,提高疾病控制率,并具有安全性。

Objective To analyze the efficacy and safety of addie injection combined with tegio and oxaliplatin(SOX)chemotherapy in the treatment of advanced esophageal cancer.Methods Eighty patients with advanced esophageal cancer treated in Anyang Sixth People’s Hospital from July 2019 to July 2021 were selected,and they were divided into control group and study group by random number table method,with 40 cases in each group.The control group received SOX chemotherapy,and the study group was treated with addie injection based on the treatment of the control group.The disease control rate and adverse reactions were compared between the two groups.The preoperative and postoperative vascular endothelial growth factor(VEGF),T lymphocyte subsets including cluster of differentiation 4^(+)(CD4^(+))and cluster of differentiation 8^(+)(CD8^(+)),tumor markers including carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125)were compared between the two groups.Results The disease control rate of the study group(77.50%,31/40)was higher than that of the control group(50.00%,20/40),P<0.05.After treatment,CD4^(+)in the study group was higher than that in the control group,while CD8^(+)was lower than that in the control group(P<0.05).After treatment,levels of VEGF,CEA and CA125 in the study group were lower than those in the control group(all P<0.05).There was no significant difference in the incidence of adverse reactions between the study group(10.00%,4/40)and the control group(25.00%,10/40),P>0.05.Conclusions Addie injection combined with SOX chemotherapy in the treatment of patients with advanced esophageal cancer can improve immune function,regulate the expression of tumor markers and VEGF,and improve the disease control rate,with good safety.